Journey Medical (DERM) vs Minerva Neurosciences (NERV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed Journey Medical (DERM) over the past year, gaining 50.0% versus a loss of 21.2%. Journey Medical is the larger company by market cap ($170.2 million vs $160.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DERM | NERV |
|---|---|---|
| Share price | $6.03 | $3.35 |
| Market cap | $170.19M | $159.95M |
| 1-day change | +1.34% | +2.45% |
| YTD return | -22.83% | -18.66% |
| 1-year return | -21.19% | +50.00% |
| 5-year return | — | -69.72% |
| EPS (TTM) | $-0.22 | $-36.12 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.56 | $12.46 |
| 52-week low | $4.31 | $2.24 |
| Distance from 52-week high | -36.89% | -73.11% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +128.03% | +208.36% |
| Average volume | 182.16K | 184.44K |
| Shares outstanding | 22.22M | 47.75M |
| Employees | 58 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed DERM by 71.2 percentage points over the past year.
About Journey Medical
DERM stock →Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
DERM vs NERV FAQ
Which is bigger, Journey Medical or Minerva Neurosciences?
Journey Medical (DERM) is larger, with a market capitalization of $170.19M compared with $159.95M for Minerva Neurosciences (NERV).
Which stock has performed better over the past year, DERM or NERV?
NERV returned +50.00% over the past 12 months, compared with -21.19% for DERM (price return, excluding dividends). Past performance does not predict future results.
Are Journey Medical and Minerva Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.